Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8736210 | 0.89 | RAB9A (0.62) | NPC1RAB9AKMT2AALDH1A1BRAF | |
| SCHEMBL697332 | 0.81 | NPC1 (0.54) | NPC1RAB9AKMT2APARP1MEN1 | |
| SCHEMBL13947485 | 0.81 | RAB9A (0.54) | NPC1RAB9AKMT2AALDH1A1BRAF | |
| SCHEMBL111544 | 0.81 | KMT2A (0.55) | NPC1RAB9AKMT2APARP1ALDH1A1 | |
| SCHEMBL7519925 | 0.81 | RAB9A (0.54) | NPC1RAB9AKMT2AALDH1A1BRAF | |
| SCHEMBL3473764 | 0.80 | RAB9A (0.70) | NPC1RAB9AKMT2AALDH1A1MEN1 | |
| SCHEMBL653441 | 0.80 | RAB9A (0.69) | NPC1RAB9AKMT2AALDH1A1MEN1 | |
| SCHEMBL112010 | 0.79 | NPC1 (0.55) | NPC1RAB9AKMT2AALDH1A1MAPT | |
| SCHEMBL28886445 | 0.78 | HTT (0.51) | NPC1RAB9AKMT2AALDH1A1MEN1 | |
| SCHEMBL112360 | 0.78 | NPC1 (0.50) | NPC1RAB9AKMT2AMEN1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758907-B1 | DIPHENYLIMIDAZOPYRIMIDINE AND -IMIDAZOLE AMINES AS INHIBITORS OF B-SECRETASE | WYETH CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090042912-A1 | DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042912-A1 | DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042912-A1 | DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-7456186-B2 | Diphenylimidazopyrimidines as inhibitors of β-secretase | WYETH (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456186-B2 | Diphenylimidazopyrimidines as inhibitors of β-secretase | WYETH (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456186-B2 | Diphenylimidazopyrimidines as inhibitors of β-secretase | WYETH (US) | 2008-11-25 | — | — | US | disclosed |
| CN-1997646-A | Diphenylimidazopyrimidines and diphenylimidazopyridines as beta-secretase inhibitors | WYETH CORP (US) | 2007-07-11 | — | — | CN | disclosed |
| EP-1758907-A1 | DIPHENYLIMIDAZOPYRIMIDINE AND -IMIDAZOLE AMINES AS INHIBITORS OF B-SECRETASE | Wyeth (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006009655-A1 | DIPHENYLIMIDAZOPYRIMIDINE AND -IMIDAZOLE AMINES AS INHIBITORS OF B-SECRETASE | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006009655-A1 | DIPHENYLIMIDAZOPYRIMIDINE AND -IMIDAZOLE AMINES AS INHIBITORS OF B-SECRETASE | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050282826-A1 | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of beta-secretase | WYETH (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042912-A1 | DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE | BACE1, BACE2, APP | NPC1 225/4885RAB9A 2545/4885KMT2A 3665/4885 |
| US-20050282826-A1 | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of beta-secretase | BACE1, BACE2, APP | NPC1 315/4885RAB9A 2935/4885KMT2A 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.